Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says

Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline...